Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

BACKGROUND: Oncolytic virus V937 showed activity and safety with intratumoral administration. This phase 1 study evaluated intravenous V937±pembrolizumab in patients with advanced solid tumors. METHODS: Patients had advanced non-small cell lung cancer (NSCLC), urothelial cancer, metastatic castratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudin, Charles M, Pandha, Hardev S, Zibelman, Matthew, Akerley, Wallace L, Harrington, Kevin J, Day, Daphne, Hill, Andrew G, O'Day, Steven J, Clay, Timothy D, Wright, Gavin M, Jennens, Ross R, Gerber, David E, Rosenberg, Jonathan E, Ralph, Christy, Campbell, David C, Curti, Brendan D, Merchan, Jaime R, Ren, Yixin, Schmidt, Emmett V, Guttman, Lisa, Gupta, Sumati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872507/
https://www.ncbi.nlm.nih.gov/pubmed/36669791
http://dx.doi.org/10.1136/jitc-2022-005007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872507/
https://www.ncbi.nlm.nih.gov/pubmed/36669791
http://dx.doi.org/10.1136/jitc-2022-005007

Ejemplares similares